News | May 12, 2023
Gilead acquires XinThera to strengthen pipeline in oncology
Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors
Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors
Pandemic was the opportunity for Ayush to develop their science and Ayush did it by developing Ayush 64, etc
The company moves a step closer towards achieving its goal of emerging as the top oncology medicine supplier from India in the ASEAN region
The certification issued by the EDQM verifies the compliance of pharmaceutical substances
The collaboration between CORONA and Ferring will cater to patients across India
Indoco expects this change in compliance status to pave the way for approvals of ANDAs submitted from this site.
The committee voted that FDA should restrict use of LYNPARZA plus abi/pred to these BRCAm mCRPC patients
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
Subscribe To Our Newsletter & Stay Updated
